Treatment of non-schizophrenic disorders: focus on atypical antipsychotics

被引:11
作者
Jeste, DV
Dolder, CR
机构
[1] Univ Calif San Diego, San Diego VA Med Ctr, La Jolla, CA 92161 USA
[2] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
关键词
D O I
10.1016/S0022-3956(03)00094-3
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Antipsychotics are commonly used for conditions other than schizophrenia, yet support for such use in the literature is unclear. This article reviews the literature on the pharmacologic treatment of specific types of non-schizophrenic disorders: those associated with psychotic depression, obsessive-compulsive disorder, body dysmorphic disorder, bipolar disorder, and dementia. It focuses on the evidence for using antipsychotics in these conditions, placing emphasis on atypical antipsychotics. Medline/HealthStar and PsycInfo databases were used to identify published trials and reports of antipsychotics used specifically for non-schizophrenic disorders. Numerous studies were found supporting the use of atypical antipsychotics for non-schizophrenic disorders; however, with the exception of dementia, few randomized, double-blind controlled trials have been published examining the efficacy and safety of these agents in non-schizophrenic disorders. In general, most trials were restricted to short-term use as adjunctive therapy. The literature reviewed was primarily comprised of small open-label trials, thus making it difficult to draw definitive conclusions. Despite the limitations of the trials reviewed, atypical antipsychotics represent a promising treatment modality when considering their improved side effect profile compared to conventional agents. Appropriate dosing and the use of antipsychotics in combination with psychosocial treatments are important treatment considerations. Due to the frequent clinical use of atypical antipsychotics as adjunctive therapy, well-designed trials of these agents in non-schizophrenic disorders are necessary. Published by Elsevier Ltd.
引用
收藏
页码:73 / 103
页数:31
相关论文
共 188 条
[11]   Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol [J].
Beasley, CM ;
Dellva, MA ;
Tamura, RN ;
Morgenstern, H ;
Glazer, WM ;
Ferguson, K ;
Tollefson, GD .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :23-30
[12]   Olanzapine compared to lithium in mania: a double-blind randomized controlled trial [J].
Berk, M ;
Ichim, L ;
Brook, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (06) :339-343
[13]  
BIEDERMAN J, 1979, ARCH GEN PSYCHIAT, V36, P327
[14]   Development of obsessive-compulsive symptoms during clozapine treatment in schizophrenia and its positive response to clomipramine [J].
Biondi, M ;
Fedele, L ;
Arcangeli, T ;
Pancheri, P .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 1999, 68 (02) :111-112
[15]   Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial [J].
Bogetto, F ;
Bellino, S ;
Vaschetto, P ;
Ziero, S .
PSYCHIATRY RESEARCH, 2000, 96 (02) :91-98
[16]  
Buckley PF, 1999, J CLIN PSYCHIAT, V60, P12
[17]   Neuroleptic sensitivity to clozapine in dementia with Lewy bodies [J].
Burke, WJ ;
Pfeiffer, RF ;
McComb, RD .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 1998, 10 (02) :227-229
[18]  
Calabrese JR, 1996, AM J PSYCHIAT, V153, P759
[19]  
CARMAN JS, 1981, J CLIN PSYCHIAT, V42, P124
[20]  
CHACKO RC, 1993, J NEUROPSYCH CLIN N, V5, P206